Presidential Symposium
Cutting edge molecular target therapy for hematologic malignancies

[PSY-2] Targeting BCL-2 in chronic lymphocytic leukemia and acute myeloid leukemia

Daniel A Pollyea^1,2, Brett M Stevens¹, Courtney L Jones¹, Amanda Winters¹, Shanshan Pei¹, Mohammad Minhajuddin¹, Angelo D'Alessandro¹, Rachel Culp-Hill¹, Kent A Riemondy¹, Austin E Gillen¹, Jay R Hesselberth¹, Diana Abbott¹, Derek Schatz¹, Jonathan A Gutman¹, Enkhtsetseg Purev¹, Clayton Smith¹, Craig T Jordan¹ (1.Division of Hematology, University of Colorado School of Medicine, United States of America, 2.University of Colorado School of Medicine, Division of Hematology, United States of America)

Dr. Daniel Pollyea received his medical degree from the University of Chicago Pritzker School of Medicine. He stayed at the University of Chicago Hospital for his residency training in internal medicine, and spent a year as Chief Medical Resident at Cook County Hospital. He completed his fellowship training in Hematology and Oncology at Stanford University, where he also earned a Masters degree in Epidemiology. He joined the faculty at the University of Colorado Division of Hematology in 2011 and was appointed the Clinical Director of Leukemia Services. His interests involve clinical and translational research involving leukemia stem cells, specifically developing novel therapies that target this population. He has over 60 peer reviewed publications, and funding from the American Society of Hematology, the American Society of Clinical Oncology and the Leukemia and Lymphoma Society.